Skip to main content

Early DMARD Initiation Benefits in Psoriatic Arthritis

Mease et al has published the results of a cohort study showing early initiation of disease-modifying antirheumatic drugs (DMARDs) in patients with psoriatic arthritis (PsA) resulted in better outcomes compared to late initiation.

A total of 291 PsA patients from the CorEvitas PsA/Spondyloarthritis Registry were studies. Early a.nd late DMARD initiators were based on whether first DMARD treatment occurred ≤1 year or >1 year after a PsA diagnosis. Outcomes included change in disease activity and patient-reported outcomes (PROs) from initiation to the six-month follow-up.

The mean time from diagnosis to DMARD initiation was 0.2 years in early initiators (n = 229, 79%) and 8.6 years in late initiators (n = 62, 21%). Early DMARD initiaion was associated with greater: 

  • MDA - minimal disease activity (adjusted risk ratio 2.01,1.03–4.40) 
  • Change in Clinical Disease Activity Index (β −3.4, 95% CI −6.2 to −0.49) 

Nonetheless, both early and late initiation of DMARD therapy experienced improvements throughout all disease activity and PROs over the six months of treatment. .

DMARDS.PsA

ADD THE FIRST COMMENT

If you are a health practitioner, you may to comment.

Due to the nature of these comment forums, only health practitioners are allowed to comment at this time.

Disclosures
The author has no conflicts of interest to disclose related to this subject
×